Rosiglitazone added to a sulphonylurea: Effective and well tolerated in patients with type 2 diabetes and mild to moderate renal impairment

PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone

“…For example, individuals with type 2 diabetes, inadequately controlled on sulphonylurea treatment, who have renal impairment – a condition where metformin therapy is contraindicated [29]. Data from three clinical trials, involving nearly 300 patients with mild‐to‐moderate renal impairment and over 500 patients with normal renal function, show that the addition of the PPARγ agonist rosiglitazone to a sulphonylurea is equally effective in both patient groups [30]. PPARγ agonists may also be used as an alternative to metformin in elderly patients with type 2 diabetes on sulphonyurea treatment, who have inadequate glycaemic control [31].…”